Quantum Leap Healthcare Collaborative
search
News

I-SPY in the News

Widely hailed as the future of phase II drug development, the adaptive I-SPY2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.
Close
Close
Close
Close
Close
Close
I-SPY Email List Sign-up

Thank you, your subscription is activated.

If you change your mind, you can unsubscribe at any time.
Oops! Something went wrong while submitting the form.
Close
Close

Highlights

I-SPY updates breast cancer subtypes with response-predictive biomarkers generated across 10 therapies

Cancer Cell

June 14, 2022

Esserman brings urgency for ‘learning healthcare’ to learn faster, better

BioCentury

June 6, 2022

Natera to Present Data from the BEATRICE and I-SPY2 Trials in Early-Stage TNBC and HR+/HER2- Breast Cancer at the 2022 AACR Annual Meeting

Natera, Inc.

April 11, 2022

Recent Coverage

December 14, 2017
-
HemOnc today
Pathologic complete response may be strong surrogate endpoint for breast cancer survival
December 12, 2017
-
BusinessWire
Key Studies Presented at SABCS Demonstrate the Important Role of MammaPrint® for Patient Pre-Selection, Cost-Effectiveness and For Younger Patients
November 29, 2017
-
Targeted Oncology
New Treatment Options Emerging for Patients With HER2+ Breast Cancer
February 23, 2017
-
R&D Magazine
Three Skills Developers Will Need to Thrive in the New Era of Genomic Medicine
January 5, 2017
-
Huffington Post
Top Ten Medical Research Issues and Trends to Watch in 2017
October 26, 2016
-
Cancer Therapy Advisor
Adaptive randomization and the I-SPY 2 trial platform
October 26, 2016
-
Clin Adv Hem Onc
The I-SPY approach to drug development: An interview with Laura Esserman
September 5, 2016
-
BioCentury
Back to School: Haste, not waste
July 7, 2016
-
NEJM
I-SPY 2 - A glimpse of future phase 2 drug development?
June 25, 2016
-
Oncology Times
I-SPY 2 shows efficacy of T-DM1-Pertuzumab
November 2, 2015
-
Managed Care Mag.
Can Platform Trials Speed Cancer Drug Development?
September 28, 2015
-
NY Times
A breast cancer surgeon who keeps challenging the status quo

The I-SPY Trials

Sponsored by Quantum Leap Healthcare Collaborative™, a 501C(3) charitable organization accelerating the union of high-impact clinical research and patient care to improve and save lives.

 
Quick Links:
Media CenterCareersInvestigator Login
© 2019  Quantum Leap Healthcare Collaborative